The planned restructuring would result in an approximately 20-25% reduction in the current workforce and will result in approximately SEK 75-85 million in annual savings when implemented.
The restructuring is subject to negotiation with relevant trade unions.
While we firmly believe this initiative is a necessary action to help us deliver on our mission, it is a difficult decision as it impacts our most valuable asset – our people.”
“This planned restructuring is an important step in our ongoing efforts to optimize our investment in key value-creating growth opportunities and position the company for long-term success. While we firmly believe this initiative is a necessary action to help us deliver on our mission, it is a difficult decision as it impacts our most valuable asset – our people. We are grateful for the commitment and relentless efforts of all our colleagues who have worked tirelessly to advance potentially lifesaving medicines for people suffering from serious immunological diseases and conditions and we remain committed to supporting those colleagues impacted by the restructure,” says Søren Tulstrup, President and CEO, Hansa Biopharma.
Photo of Søren Tulstrup: Hansa Biopharma
